0.76
-0.0129(-1.66%)
Currency In USD
| Previous Close | 0.78 |
| Open | 0.74 |
| Day High | 0.76 |
| Day Low | 0.73 |
| 52-Week High | 7.04 |
| 52-Week Low | 0.6 |
| Volume | 38,725 |
| Average Volume | 309,095 |
| Market Cap | 3.36M |
| PE | -0.08 |
| EPS | -10.19 |
| Moving Average 50 Days | 0.77 |
| Moving Average 200 Days | 2.21 |
| Change | -0.01 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of May 09, 2025 at a share price of $0.765. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 5 years ago, it would be worth $0.21 as of May 09, 2025 at a share price of $0.765.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases
GlobeNewswire Inc.
May 06, 2025 12:30 PM GMT
Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit
GlobeNewswire Inc.
May 01, 2025 12:30 PM GMT
Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living w
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
GlobeNewswire Inc.
Apr 09, 2025 12:30 PM GMT
Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability of PALI-2108 No serious adverse events (SAEs